Abstract:Introduction: Recently we reported that insulin receptor substrate 1 (IRS-1), classically an adaptor protein for the insulin-like growth factor type I receptor (IGF-IR), associates with the epidermal growth factor receptor in oestrogen receptor (ER)-positive (ER+) tamoxifen-resistant breast cancer cells. In this study, we examined whether IRS-1 also associates with another erbB receptor family member, erbB3, and what impact this might have on IGF-IR signalling in three ER+ breast cancer cell lines. Methods: Immunoprecipitation and Western blot analysis were utilised to examine the potential association between erbB3 and IRS-1 in MCF-7, T47D and BT-474 cells in the absence and presence of the erbB3/4 ligand heregulin β1 (HRGβ1). Subsequently, the impact of a selective IGF-IR/IR inhibitor 4-anilino-5-bromo-2-[4-(2-hydroxy-3-(N, N-dimethylamino)propoxy)anilino]pyrimidine on this association and HRGβ1 signalling was assessed in these cell lines. Immunohistochemical analysis of a small cohort of ER+ breast cancer patient samples was also performed to determine the potential clinical relevance of this novel interaction. Results: Immunoprecipitation and Western blot analysis revealed an interaction between erbB3 and IRS-1 in MCF-7, T47D and BT-474 cells, with HRGβ1 significantly enhancing this recruitment and promoting IRS-1 phosphorylation at Y612. IRS-1 participates in erbB3 signalling in MCF-7 and T47D cells as IRS-1 knockdown impaired HRGβ1 signalling. Importantly, recruitment of IRS-1 by erbB3 reduced IRS-1 association with IGF-IR in MCF-7 and T47D cells, whilst blockade of IGF-IR-enhanced erbB3-IRS-1 interaction and sensitised both cell lines to HRGβ1, allowing HRGβ1 to override IGF-IR blockade. Consequently, suppression of IRS-1 signalling enhanced the effects of IGF-IR inhibition in these cells. This novel interaction may have clinical relevance, as immunohistochemical analysis of a small ER+ breast tumour series revealed significant positive correlations between phosphorylated IRS-1 Y612 expression and total erbB3, phosphorylated Akt and Ki-67 expression. Conclusions: IRS-1 can be recruited to IGF-IR and erbB3 in ER+ breast cancer cells, and this provides an adaptive resistance mechanism when these receptors are targeted individually. Consequently, cotargeting IGF-IR and either erbB3 or IRS-1 should prove to be a more effective strategy for the treatment of ER+ breast cancer.

The E3 Ligase TRAF4 Promotes IGF Signaling by Mediating Atypical Ubiquitination of IRS-1

The E3 Ligase Traf6 Regulates Akt Ubiquitination and Activation

mTORC1/S6K1 signaling promotes sustained oncogenic translation through modulating CRL3 -mediated non-degradative ubiquitination of eIF4A1

TRAF4‐Mediated LAMTOR1 Ubiquitination Promotes mTORC1 Activation and Inhibits the Inflammation‐Induced Colorectal Cancer Progression

Distinct signalling properties of insulin receptor substrate (IRS)-1 and IRS-2 in mediating insulin/IGF-1 action

IRS4 promotes the progression of non-small cell lung cancer and confers resistance to EGFR-TKI through the activation of PI3K/Akt and Ras-MAPK pathways

erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines

mTORC1/S6K1 signaling promotes sustained oncogenic translation through modulating CRL3 IBTK -mediated ubiquitination of eIF4A1 in cancer cells

FER-mediated phosphorylation and PIK3R2 recruitment on IRS4 promotes AKT activation and tumorigenesis in ovarian cancer cells

TRAF2: a Double-Edged Sword?

Mtorc1/s6k1 Signaling Promotes Sustained Oncogenic Translation Through Modulating CRL3IBTK-mediated Non-Degradative Ubiquitination of Eif4a1

E3 Ubiquitin Ligases: Key Regulators of TGFβ Signaling in Cancer Progression

E3 Ubiquitin Ligases: Key Regulators of TGF Signaling in Cancer Progression

Activation of insulin-like growth factor-1 receptor (IGF-1R) promotes growth of colorectal cancer through triggering the MEX3A-mediated degradation of RIG-I

Phase Separation of Insulin Receptor Substrate 1 Drives the Formation of Insulin/igf-1 Signalosomes

Ubiquitination of Rheb governs growth factor-induced mTORC1 activation

TRAF4 Promotes TGF-β Receptor Signaling and Drives Breast Cancer Metastasis.

USP4 is Regulated by AKT Phosphorylation and Directly Deubiquitylates TGF-β Type I Receptor

E3 ubiquitin ligase SIAH1 mediates ubiquitination and degradation of TRB3

Tumor Necrosis Factor Receptor-associated Factor Family Protein 2 is a Key Mediator of the Epidermal Growth Factor-induced Ribosomal S6 Kinase 2/Camp-Responsive Element-binding Protein/Fos Protein Signaling Pathway*

USP4 is regulated by AKT phosphorylation and directly deubiquitylates TGF-[beta] type I receptor